Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Enterprise Value (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Enterprise Value for 4 consecutive years, with -$40.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Enterprise Value rose 61.04% to -$40.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$40.6 million, a 61.04% increase, with the full-year FY2024 number at -$40.6 million, up 61.04% from a year prior.
  • Enterprise Value was -$40.6 million for Q4 2024 at Lyra Therapeutics, up from -$53.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$34.1 million in Q1 2022 to a low of -$122.4 million in Q2 2022.
  • A 4-year average of -$77.6 million and a median of -$78.4 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: crashed 146.74% in 2023, then surged 61.04% in 2024.
  • Lyra Therapeutics' Enterprise Value stood at -$46.1 million in 2021, then crashed by 115.48% to -$99.3 million in 2022, then fell by 4.89% to -$104.1 million in 2023, then soared by 61.04% to -$40.6 million in 2024.
  • Per Business Quant, the three most recent readings for LYRA's Enterprise Value are -$40.6 million (Q4 2024), -$53.6 million (Q3 2024), and -$69.5 million (Q2 2024).